Gapping up
In reaction to strong earnings/guidance/SSS: NSPH +37.9%, MGCD +13.3%, (also reports unresolved manufacturer issue), ZUMZ +11.1%, (Zumiez reports December comparable sales -8.9% vs -13.8% Retail Metrics consensus; raises Q4 outlook based primarily on better than expected sales), MG +7.2%, FRAN +2.8%, GBX +1.9%, PLCE +1.3%, M +1.1%, (Macy's reports November and December comp store sales declined 4.7% y/y; Lowers 2015 EPS guidance), QUAD +0.8%
M&A news: EZCH +2.8% (Raging Capital supports transaction with Mellanox (MLNX))
Select gold/silver stocks trading higher: HMY +9.8%, GFI +3.3%, ABX +2.3%, NEM +2.2%, AEM +2.1%, GOLD +2%, GDX +1.5%, PAAS +1.3%, .
Other news: CRDC +42.9% (amended license agreement with Intuitive Surgical (ISRG)), DVAX +29.8% (reports top line results of Phase 3 HEPLISAV-B study; Both co-primary endpoints were met), BIND +14.7% (Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer), QURE +12% (announced it will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial tomorrow morning), MSTX +7% (provides business update, Enrollment in largest-ever interventional Phase 3 trial in sickle cell disease has surpassed 90%), ZIXI +2.7% (approves $15 mln share repurchase program), DNN +2.7% (announced that preparations for its 2016 uranium exploration programs in the Athabasca Basin have commenced and that exploration drilling is scheduled to begin on January 12), CCO +2.5% (following late move higher on LAMR asset interest)
In reaction to strong earnings/guidance/SSS: NSPH +37.9%, MGCD +13.3%, (also reports unresolved manufacturer issue), ZUMZ +11.1%, (Zumiez reports December comparable sales -8.9% vs -13.8% Retail Metrics consensus; raises Q4 outlook based primarily on better than expected sales), MG +7.2%, FRAN +2.8%, GBX +1.9%, PLCE +1.3%, M +1.1%, (Macy's reports November and December comp store sales declined 4.7% y/y; Lowers 2015 EPS guidance), QUAD +0.8%
M&A news: EZCH +2.8% (Raging Capital supports transaction with Mellanox (MLNX))
Select gold/silver stocks trading higher: HMY +9.8%, GFI +3.3%, ABX +2.3%, NEM +2.2%, AEM +2.1%, GOLD +2%, GDX +1.5%, PAAS +1.3%, .
Other news: CRDC +42.9% (amended license agreement with Intuitive Surgical (ISRG)), DVAX +29.8% (reports top line results of Phase 3 HEPLISAV-B study; Both co-primary endpoints were met), BIND +14.7% (Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer), QURE +12% (announced it will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial tomorrow morning), MSTX +7% (provides business update, Enrollment in largest-ever interventional Phase 3 trial in sickle cell disease has surpassed 90%), ZIXI +2.7% (approves $15 mln share repurchase program), DNN +2.7% (announced that preparations for its 2016 uranium exploration programs in the Athabasca Basin have commenced and that exploration drilling is scheduled to begin on January 12), CCO +2.5% (following late move higher on LAMR asset interest)